Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Century Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Century Therapeutics, Inc.’s stock price such as:

• Century Therapeutics, Inc.’s current stock price and volume
• Why Century Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for IPSC from analysts
• IPSC’s stock price momentum as measured by its relative strength

About Century Therapeutics, Inc. (IPSC)

Before we jump into Century Therapeutics, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial. In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Want to learn more about Century Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Century Therapeutics, Inc..

Century Therapeutics, Inc.’s Stock Price as of Market Close

As of March 06, 2026, 4:00 PM, CST, Century Therapeutics, Inc.’s stock price was $2.560.

Century Therapeutics, Inc. is 0% from its previous closing price of $2.560.

During the last market session, Century Therapeutics, Inc.’s stock traded between $2.445 and $2.610. Currently, there are approximately 86.46 million shares outstanding for Century Therapeutics, Inc..

Century Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Century Therapeutics, Inc. Stock Price History

Century Therapeutics, Inc.’s (IPSC) price is currently up 10.34% so far this month.

During the month of March, Century Therapeutics, Inc.’s stock price has reached a high of $2.650 and a low of $2.105.

Over the last year, Century Therapeutics, Inc. has hit prices as high as $2.710 and as low as $0.342. Year to date, Century Therapeutics, Inc.’s stock is up 157.34%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Century Therapeutics, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 05, 2026, there was 1 analyst who downgraded Century Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Century Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Century Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Century Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Century Therapeutics, Inc. (IPSC) by visiting AAII Stock Evaluator.

Relative Price Strength of Century Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 05, 2026, Century Therapeutics, Inc. has a weighted four-quarter relative price strength of 154.90%, which translates to a Momentum Score of 100 and is considered to be Very Strong.

Want to learn more about how Century Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Century Therapeutics, Inc. Stock Price: Bottom Line

As of March 6, 2026, Century Therapeutics, Inc.’s stock price is $2.560, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Century Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.